Immunotherapy in Patient With Poor General Condition

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

September 26, 2025

Conditions
Non-small Cell Lung Cancer Stage IV
Interventions
DRUG

Durvalumab

1500 mg IV every 4 weeks

Trial Locations (20)

14000

Caen - CHU Côte de Nacre, Caen

34295

Montpellier - CHRU, Montpellier

44805

Nantes - ICO Site René Gauducheau, Nantes

72000

Centre Hospitalier - Pneumologie, Le Mans

75020

AP-HP Hopital Tenon - Pneumologie, Paris

Unknown

Besançon - CHU, Besançon

Hôpital Ambroise Paré - Pneumologie, Boulogne

CH, Colmar

CHRU Grenoble, Grenoble

CHRU de Lille, Lille

AP-HM Hopital Nord, Marseille

GRH Mulhouse Sud-Alsace, Mulhouse

Nancy - Institut de Cancérologie de Lorraine, Nancy

CHR d'Orléans La Source, Orléans

Paris - APHP Bichat, Paris

Paris - Curie, Paris

Lyon - URCOT, Pierre-Bénite

CHU Strasbourg, Strasbourg

CHU Toulouse - Pneumologie, Toulouse

CHU Tours - Pneumologie, Tours

All Listed Sponsors
lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER

NCT04108026 - Immunotherapy in Patient With Poor General Condition | Biotech Hunter | Biotech Hunter